TABLE 1

FDA-approved parenteral NP products containing active pharmaceutical ingredients on the U.S. market as of October 2018

Trade NameActive Pharmaceutical IngredientFormulationAverage Diameter, nmRoute of AdministrationApproval Year
DoxilDoxorubicinLiposome85Intravenous1995
DaunoXomeDaunorubicinLiposome45Intravenous1996
AmBisomeAmphotericin BLiposome60–70Intravenous1997
VisudyneVerteporfinLiposome18–104Intravenous2000
MarqiboVincristine sulfateLiposome100Intravenous2012
OnivydeIrinotecan HCLLiposome110Intravenous2015
VyxeosDaunorubicin/cytarabineLiposome100Intravenous2017
AbraxanePaclitaxelNanoparticle130Intravenous2005
SomatulineLanreotide acetateNanotube24Subcutaneous2007
AbelcetAmphotericin BLipid complex1600–11,100Intravenous1995
AmphotecAmphotericin BLipid complex150Intravenous1996
OnpattroPatisiranLipid complex<100Intravenous2018
  • Note that Abelcet is included in an FDA NP product list (Bobo et al., 2016; Zheng et al., 2017) but has been reported to have an average diameter of >1000 nm (Clark et al., 1991; Johnson et al., 1998).